Abstract
Immunomodulation of the gut associated lynphoid tissue is a key issue in the clinical management of inflammatory bowel disease (IBD). Often toxic drugs are used to obtain clinical remission, sometimes in already immunocompromized patients. The presence of important co-morbidity might also heavily affect the clinical strategy. Polyunsaturated fatty acids (PUFAs) might represent a valid therapeutical option in IBD patients and further controlled clinical studies are warranted.
Original language | English |
---|---|
Article number | 15 |
Journal | JRSM Open |
Volume | 1 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Jun 2010 |